389 related articles for article (PubMed ID: 24406151)
1. Melatonin, selective and non-selective MT1/MT2 receptors agonists: differential effects on the 24-h vigilance states.
Ochoa-Sanchez R; Comai S; Spadoni G; Bedini A; Tarzia G; Gobbi G
Neurosci Lett; 2014 Feb; 561():156-61. PubMed ID: 24406151
[TBL] [Abstract][Full Text] [Related]
2. Sleep-wake characterization of double MT₁/MT₂ receptor knockout mice and comparison with MT₁ and MT₂ receptor knockout mice.
Comai S; Ochoa-Sanchez R; Gobbi G
Behav Brain Res; 2013 Apr; 243():231-8. PubMed ID: 23333399
[TBL] [Abstract][Full Text] [Related]
3. Melatonin MT
López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
[TBL] [Abstract][Full Text] [Related]
4. Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: comparison with melatonin and diazepam.
Ochoa-Sanchez R; Rainer Q; Comai S; Spadoni G; Bedini A; Rivara S; Fraschini F; Mor M; Tarzia G; Gobbi G
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):318-25. PubMed ID: 22789661
[TBL] [Abstract][Full Text] [Related]
5. Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat.
Fisher SP; Davidson K; Kulla A; Sugden D
J Pineal Res; 2008 Sep; 45(2):125-32. PubMed ID: 18298466
[TBL] [Abstract][Full Text] [Related]
6. Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic Pain.
Posa L; De Gregorio D; Gobbi G; Comai S
Curr Med Chem; 2018; 25(32):3866-3882. PubMed ID: 28183259
[TBL] [Abstract][Full Text] [Related]
7. Antinociceptive properties of selective MT(2) melatonin receptor partial agonists.
López-Canul M; Comai S; Domínguez-López S; Granados-Soto V; Gobbi G
Eur J Pharmacol; 2015 Oct; 764():424-432. PubMed ID: 26162699
[TBL] [Abstract][Full Text] [Related]
8. Specific melatonin receptor promotes a deeper sleep.
Harrington M
Lab Anim (NY); 2012 Jan; 41(2):31. PubMed ID: 22261877
[No Abstract] [Full Text] [Related]
9. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
[TBL] [Abstract][Full Text] [Related]
10. Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat.
Fisher SP; Sugden D
Neurosci Lett; 2009 Jun; 457(2):93-6. PubMed ID: 19429170
[TBL] [Abstract][Full Text] [Related]
11. Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways.
Lopez-Canul M; Palazzo E; Dominguez-Lopez S; Luongo L; Lacoste B; Comai S; Angeloni D; Fraschini F; Boccella S; Spadoni G; Bedini A; Tarzia G; Maione S; Granados-Soto V; Gobbi G
Pain; 2015 Feb; 156(2):305-317. PubMed ID: 25599452
[TBL] [Abstract][Full Text] [Related]
12. Melatonin recovers sleep phase delayed by MK-801 through the melatonin MT
Wang Q; Zhu D; Ping S; Li C; Pang K; Zhu S; Zhang J; Comai S; Sun J
J Pineal Res; 2020 Oct; 69(3):e12674. PubMed ID: 32535982
[TBL] [Abstract][Full Text] [Related]
13. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand.
Ochoa-Sanchez R; Comai S; Lacoste B; Bambico FR; Dominguez-Lopez S; Spadoni G; Rivara S; Bedini A; Angeloni D; Fraschini F; Mor M; Tarzia G; Descarries L; Gobbi G
J Neurosci; 2011 Dec; 31(50):18439-52. PubMed ID: 22171046
[TBL] [Abstract][Full Text] [Related]
14. Sleep well. Untangling the role of melatonin MT1 and MT2 receptors in sleep.
Gobbi G; Comai S
J Pineal Res; 2019 Apr; 66(3):e12544. PubMed ID: 30586215
[TBL] [Abstract][Full Text] [Related]
15. Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT
Tchekalarova J; Kortenska L; Ivanova N; Atanasova M; Marinov P
Psychopharmacology (Berl); 2020 Feb; 237(2):503-518. PubMed ID: 31720718
[TBL] [Abstract][Full Text] [Related]
16. Short-term effects of melatonin and pinealectomy on serotonergic neuronal activity across the light-dark cycle.
Domínguez-López S; Mahar I; Bambico FR; Labonté B; Ochoa-Sánchez R; Leyton M; Gobbi G
J Psychopharmacol; 2012 Jun; 26(6):830-44. PubMed ID: 21730015
[TBL] [Abstract][Full Text] [Related]
17. N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands.
Rivara S; Vacondio F; Fioni A; Silva C; Carmi C; Mor M; Lucini V; Pannacci M; Caronno A; Scaglione F; Gobbi G; Spadoni G; Bedini A; Orlando P; Lucarini S; Tarzia G
ChemMedChem; 2009 Oct; 4(10):1746-55. PubMed ID: 19728346
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in melatonin receptor ligands.
Zlotos DP
Arch Pharm (Weinheim); 2005 Jun; 338(5-6):229-47. PubMed ID: 15952241
[TBL] [Abstract][Full Text] [Related]
19. Melatonin-enhanced hyperactivation of hamster sperm.
Fujinoki M
Reproduction; 2008 Nov; 136(5):533-41. PubMed ID: 18715981
[TBL] [Abstract][Full Text] [Related]
20. The glycolytic metabolite methylglyoxal induces changes in vigilance by generating low-amplitude non-REM sleep.
Jakubcakova V; Curzi ML; Flachskamm C; Hambsch B; Landgraf R; Kimura M
J Psychopharmacol; 2013 Nov; 27(11):1070-5. PubMed ID: 23828824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
